invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial
Up to 45% of the trial costs for the dose-determining Phase 1b trial will be funded by the Austrian research promotion agency.
Up to 45% of the trial costs for the dose-determining Phase 1b trial will be funded by the Austrian research promotion agency.
What's Your Reaction?
